Co-Diagnostics Secures First Patent for Point-of-Care PCR Platform in Australia
核心洞察
Co-Diagnostics (搜索) received its first patent grant for the Co-Dx PCR platform (搜索) from the Australian Patent Office (搜索), providing broad protection for the company's proprietary nucleic acid detection system.
The patent covers the design and operation of the Co-Dx PCR Pro instrument and test cups, enabling high-quality PCR testing outside traditional laboratory environments.
The platform leverages Co-Primers (搜索) technology to deliver gold-standard PCR accuracy in a compact device for decentralized testing of infectious diseases including flu (搜索), COVID (搜索), and RSV (搜索).
Co-Diagnostics (搜索) Inc has received its first patent grant for its novel point-of-care PCR platform from the Australian Patent Office (搜索), marking a significant milestone in the company's intellectual property strategy. Australian Patent No. AU2022270084A1, initially filed in May 2022 and granted in June 2025, provides broad protection for the company's proprietary system and methods used for nucleic acid detection and analysis.
Platform Technology and Design
The patent specifically covers the design and operation of the Co-Dx PCR Pro instrument and test cups, including the platform's approach to performing high-quality polymerase chain reaction testing outside of traditional laboratory environments. The Co-Dx PCR platform (搜索) is designed to deliver gold-standard PCR accuracy in a compact, user-friendly device suitable for decentralized testing environments.
The platform leverages Co-Diagnostics (搜索)' patented Co-Primers (搜索) technology and is intended to enable rapid, sensitive, and specific molecular diagnostics across a broad range of infectious disease applications. The system includes the Co-Dx PCR Home, Co-Dx PCR Pro, mobile app, and all associated tests and software.
Strategic Market Protection
"This patent represents another significant milestone in securing global protection for our technology as we continue expanding the potential applications of the point-of-care PCR platform," said Dwight Egan, CEO of Co-Diagnostics (搜索). "From the beginning, Co-Dx's goal has been to make accurate, accessible PCR testing available where it is needed most, and strengthening our global IP portfolio is essential to that mission."
The patent grant provides strategic protection in a region where Co-Diagnostics (搜索) and potential commercial partners may choose to introduce or distribute the Co-Dx PCR platform (搜索) in the future. Australia recently experienced a record-breaking flu (搜索) season, making patent coverage in this market a key defensive measure to protect the commercial potential of the platform.
Clinical Development Pipeline
The patent protection extends to the Co-Dx PCR Flu (搜索) A/B, COVID (搜索), RSV (搜索) multiplex test, which is currently undergoing clinical performance testing. This multiplex capability positions the platform to address multiple respiratory pathogens simultaneously, addressing a significant clinical need for comprehensive point-of-care testing.
Regulatory Status
The Co-Dx PCR platform (搜索), including all associated tests and software, remains subject to review by the US Food and Drug Administration and other regulatory bodies and is not currently available for sale. The company continues to work toward regulatory approval for its point-of-care testing solutions.
Co-Diagnostics (搜索), a Utah-based molecular diagnostics company, develops, manufactures and markets diagnostic technologies utilizing the detection and analysis of nucleic acid molecules. The company uses its proprietary technology to design specific tests for both infectious disease applications and genetic marker identification beyond infectious disease testing.